Literature DB >> 16936187

Diabetic retinopathy: seeing beyond glucose-induced microvascular disease.

David A Antonetti1, Alistair J Barber, Sarah K Bronson, Willard M Freeman, Thomas W Gardner, Leonard S Jefferson, Mark Kester, Scot R Kimball, J Kyle Krady, Kathryn F LaNoue, Christopher C Norbury, Patrick G Quinn, Lakshman Sandirasegarane, Ian A Simpson.   

Abstract

Diabetic retinopathy remains a frightening prospect to patients and frustrates physicians. Destruction of damaged retina by photocoagulation remains the primary treatment nearly 50 years after its introduction. The diabetes pandemic requires new approaches to understand the pathophysiology and improve the detection, prevention, and treatment of retinopathy. This perspective considers how the unique anatomy and physiology of the retina may predispose it to the metabolic stresses of diabetes. The roles of neural retinal alterations and impaired retinal insulin action in the pathogenesis of early retinopathy and the mechanisms of vision loss are emphasized. Potential means to overcome limitations of current animal models and diagnostic testing are also presented with the goal of accelerating therapies to manage retinopathy in the face of ongoing diabetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16936187     DOI: 10.2337/db05-1635

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  278 in total

1.  Plasma kallikrein and diabetic macular edema.

Authors:  Edward P Feener
Journal:  Curr Diab Rep       Date:  2010-08       Impact factor: 4.810

2.  Impaired glucose tolerance plus hyperlipidaemia induced by diet promotes retina microaneurysms in New Zealand rabbits.

Authors:  Tatiana Helfenstein; Francisco A Fonseca; Sílvia S Ihara; Juliana M Bottós; Flávio T Moreira; Henrique Pott; Michel E Farah; Maria C Martins; Maria C Izar
Journal:  Int J Exp Pathol       Date:  2011-02       Impact factor: 1.925

3.  Induction of ischemic tolerance protects the retina from diabetic retinopathy.

Authors:  Diego C Fernandez; Pablo H Sande; Mónica S Chianelli; Hernán J Aldana Marcos; Ruth E Rosenstein
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

4.  Electrophysiological studies in newly onset type 2 diabetes without visible vascular retinopathy.

Authors:  M Tyrberg; U Lindblad; A Melander; M Lövestam-Adrian; V Ponjavic; S Andréasson
Journal:  Doc Ophthalmol       Date:  2011-11-06       Impact factor: 2.379

5.  Novel atypical PKC inhibitors prevent vascular endothelial growth factor-induced blood-retinal barrier dysfunction.

Authors:  Paul M Titchenell; Cheng-Mao Lin; Jason M Keil; Jeffrey M Sundstrom; Charles D Smith; David A Antonetti
Journal:  Biochem J       Date:  2012-09-15       Impact factor: 3.857

6.  Dysfunction of circulating endothelial progenitor cells in type 1 diabetic rats with diabetic retinopathy.

Authors:  Wei Zhang; Hua Yan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-02-06       Impact factor: 3.117

7.  NAD(P)H oxidase-dependent regulation of CCL2 production during retinal inflammation.

Authors:  Wenbo Zhang; Modesto Rojas; Brenda Lilly; Nai-Tse Tsai; Tahira Lemtalsi; Gregory I Liou; Robert W Caldwell; Ruth B Caldwell
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-02-21       Impact factor: 4.799

8.  Dopamine deficiency contributes to early visual dysfunction in a rodent model of type 1 diabetes.

Authors:  Moe H Aung; Han Na Park; Moon K Han; Tracy S Obertone; Jane Abey; Fazila Aseem; Peter M Thule; P Michael Iuvone; Machelle T Pardue
Journal:  J Neurosci       Date:  2014-01-15       Impact factor: 6.167

Review 9.  The role of O-GlcNAc signaling in the pathogenesis of diabetic retinopathy.

Authors:  Richard D Semba; Hu Huang; Gerard A Lutty; Jennifer E Van Eyk; Gerald W Hart
Journal:  Proteomics Clin Appl       Date:  2014-02-19       Impact factor: 3.494

10.  Retinal angiogenesis in the Ins2(Akita) mouse model of diabetic retinopathy.

Authors:  Zongchao Han; Junjing Guo; Shannon M Conley; Muna I Naash
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-17       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.